Every filing for 44975P103 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
HHLR Advisors, Ltd.
13D/A
Amendment 6
|
4.9% |
11/5/2026
Event 11/5/2026
|
|
| HHLR Advisors, Ltd. | 4.9% | ||
| Hillhouse Investment Management, Ltd. | 4.9% | ||
|
CBC Investment I-Mab Ltd
13D/A
Amendment 2
|
11.5% |
2/3/2026
Event 1/29/2026
|
|
| CBC Investment I-Mab Limited | 4.4% | ||
| IBC Investment Seven Limited | 1.4% | ||
| CBC Spvii Limited | 2.1% | ||
| C-Bridge II Investment Ten Limited | 0.9% | ||
| Nova Aqua Limited | 2.7% | ||
| C-Bridge Healthcare Fund II, L.P. | 5.3% | ||
| C-Bridge Healthcare Fund GP II, L.P. | 5.3% | ||
| C-Bridge Capital GP, Ltd. | 8.8% | ||
| I-Bridge Healthcare Fund, L.P. | 3.5% | ||
| I-Bridge Healthcare GP, L.P. | 3.5% | ||
| I-Bridge Capital GP, Ltd. | 3.5% | ||
| Wei Fu | 11.5% | ||
|
CBC Investment I-Mab Ltd
13D/A
Amendment 1
|
10.4% |
8/7/2025
Event 8/5/2025
|
|
| CBC Investment I-Mab Limited | 4.5% | ||
| IBC Investment Seven Limited | 1.4% | ||
| CBC Spvii Limited | 2.1% | ||
| C-Bridge II Investment Ten Limited | 0.9% | ||
| Nova Aqua Limited | 1.6% | ||
| C-Bridge Healthcare Fund II, L.P. | 5.4% | ||
| C-Bridge Healthcare Fund GP II, L.P. | 5.4% | ||
| C-Bridge Capital GP, Ltd. | 8.8% | ||
| I-Bridge Healthcare Fund, L.P. | 3.5% | ||
| I-Bridge Healthcare GP, L.P. | 3.5% | ||
| I-Bridge Capital GP, Ltd. | 3.5% | ||
| Wei Fu | 10.4% | ||
| Everest Medicines Ltd 13D | 16.1% |
8/5/2025
Event 8/5/2025
|
|
|
CBC Investment I-Mab Ltd
13D
|
17.9% |
2/5/2025
Event 1/29/2025
|
|
| CBC Investment I-Mab Limited | 6.3% | ||
| IBC Investment Seven Limited | 1.9% | ||
| CBC Spvii Limited | 3.0% | ||
| C-Bridge II Investment Ten Limited | 1.3% | ||
| Everest Medicines Limited | 3.2% | ||
| Nova Aqua Limited | 2.2% | ||
| C-Bridge Healthcare Fund II, L.P. | 7.6% | ||
| C-Bridge Healthcare Fund GP II, L.P. | 7.6% | ||
| C-Bridge Capital GP, Ltd. | 12.5% | ||
| I-Bridge Healthcare Fund, L.P. | 4.9% | ||
| I-Bridge Healthcare GP, L.P. | 4.9% | ||
| I-Bridge Capital GP, Ltd. | 4.9% | ||
| Wei Fu | 17.9% |
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 15 | 1.75 M | $2.39M |
| 2026 Q2 | 49 | 24.7 M | $48.1M |
| 2026 Q1 | 49 | 29.3 M | $72.1M |
| 2025 Q4 | 58 | 33.2 M | $132M |
| 2025 Q3 | 43 | 29.8 M | $113M |
| 2025 Q2 | 34 | 9.40 M | $22.7M |
| 2025 Q1 | 31 | 8.99 M | $7.41M |
| 2024 Q4 | 29 | 11.9 M | $10.1M |
| 2024 Q3 | 29 | 14.2 M | $17.6M |
| 2024 Q2 | 39 | 15.2 M | $25.4M |
| 2024 Q1 | 41 | 12.2 M | $22.7M |
| 2023 Q4 | 45 | 13.0 M | $24.7M |
| 2023 Q3 | 49 | 15.3 M | $20.1M |
| 2023 Q2 | 49 | 18.7 M | $55.9M |
| 2023 Q1 | 55 | 20.7 M | $71.6M |
| 2022 Q4 | 71 | 25.4 M | $106M |
| 2022 Q3 | 76 | 30.8 M | $123M |
| 2022 Q2 | 98 | 40.8 M | $459M |
| 2022 Q1 | 122 | 40.8 M | $666M |
| 2021 Q4 | 134 | 39.2 M | $1.86B |
| 2021 Q3 | 145 | 36.1 M | $2.61B |
| 2021 Q2 | 138 | 28.3 M | $2.38B |
| 2021 Q1 | 82 | 23.3 M | $1.13B |
| 2020 Q4 | 66 | 14.8 M | $699M |
| 2020 Q3 | 49 | 9.53 M | $448M |
| 2020 Q2 | 21 | 4.68 M | $139M |
| 2020 Q1 | 17 | 4.68 M | $60.8M |